← Leaderboards
Jochen Reiser
Massachusetts General Hospital
$12,583,911
Attributed
$16,295,092
Total exposure
9
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.7M · FY2006–25$2M$1.5M$1M$500K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$16,295,092 · 9
By mechanism
R01$16,295,092 · 9
Top collaborators
- Minnie M Sarwal6 shared
- Vineet Gupta4 shared
- Eunsil Hahm3 shared
- Rulan S Parekh3 shared
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- M. Amin Arnaout$31,171,564
- Bradley T Hyman$51,936,441
- Tatsuo Kawai$13,661,886
- Roy Soberman$7,702,299
- Djamel Lebeche$7,694,093
Others in their field
Top investigators on “Kidney”
- Jeffrey P Krischer · University Of South Florida$540,222,210
- John M Lachin · George Washington University$155,894,464
- David M Nathan · Massachusetts Institute Of Technology$127,229,266
- Kathryn Hirst · Caritas St. Elizabeth'S Medical Center$111,521,899
- David Heimbrook · Leidos Biomedical Research, Inc.$83,221,586
- Peter Scott Heeger · Case Western Reserve University$80,562,246
Research focus
KidneyKidney DiseasesIn VivoPodocyteProteinuriaInjuryIn VitroProteinsCellsBaseFoot ProcessRenal Glomerular DiseaseAffectFocal Segmental GlomerulosclerosisMediatingSignal TransductionBiochemicalProgramsUrokinase Plasminogen Activator ReceptorRodentNovel TherapeuticsPathogenesisAnimal ModelMouse Model
Grant awards (45)
Targeting bone marrow to treat renal disease$424,750
R01 · FY2025 · DK · contact PI
Targeting bone marrow to treat renal disease$489,477
R01 · FY2024 · DK · contact PI
Targeting bone marrow to treat renal disease$607,942
R01 · FY2023 · DK · contact PI
suPAR and renal fibrosis$249,267
R01 · FY2023 · DK · contact PI
suPAR and renal fibrosis$450,415
R01 · FY2022 · DK · contact PI
CD40 autoantibody and FSGS recurrence$523,497
R01 · FY2021 · DK
suPAR and renal fibrosis$450,415
R01 · FY2021 · DK · contact PI
CD40 autoantibody and FSGS recurrence$542,692
R01 · FY2020 · DK
The KIDCOV Study: Assessment of Kidney Injury and Associated Risk Factors for SARS-CoV-2$459,623
R01 · FY2020 · DK
suPAR and renal fibrosis$459,139
R01 · FY2020 · DK · contact PI
suPAR and APOL1-CKD in Sub-Saharan Africa$192,499
R01 · FY2020 · DK · contact PI
CD40 autoantibody and FSGS recurrence$549,397
R01 · FY2019 · DK
Novel Anti-Proteinuric Strategies Targeting Podocytes$460,320
R01 · FY2019 · DK
suPAR and APOL1-CKD in Sub-Saharan Africa$192,499
R01 · FY2019 · DK · contact PI
CD40 autoantibody and FSGS recurrence$556,428
R01 · FY2018 · DK
suPAR and APOL1-CKD in Sub-Saharan Africa$504,931
R01 · FY2018 · DK · contact PI
Novel Anti-Proteinuric Strategies Targeting Podocytes$447,180
R01 · FY2018 · DK
CD40 autoantibody and FSGS recurrence$560,227
R01 · FY2017 · DK
Role of Circulating suPAR in FSGS$464,263
R01 · FY2017 · DK · contact PI
Novel Anti-Proteinuric Strategies Targeting Podocytes$447,180
R01 · FY2017 · DK
A Humanized Mouse Model of FSGS$209,250
R01 · FY2017 · DK · contact PI
Role of Circulating suPAR in FSGS$504,471
R01 · FY2016 · DK · contact PI
Novel Anti-Proteinuric Strategies Targeting Podocytes$463,720
R01 · FY2016 · DK
A Humanized Mouse Model of FSGS$209,250
R01 · FY2016 · DK · contact PI
Role of Circulating suPAR in FSGS$513,094
R01 · FY2015 · DK · contact PI
Enzymatic Regulation of the Podocyte$229,500
R01 · FY2015 · DK · contact PI
A Humanized Mouse Model of FSGS$209,250
R01 · FY2015 · DK · contact PI
Role of Circulating suPAR in FSGS$522,856
R01 · FY2014 · DK · contact PI
Glomerular Disease Mechanisms mediated by Podocyte TRPC6$307,549
R01 · FY2014 · DK · contact PI
Enzymatic Regulation of the Podocyte$229,500
R01 · FY2014 · DK · contact PI
Role of Circulating suPAR in FSGS$548,587
R01 · FY2013 · DK · contact PI
Glomerular Disease Mechanisms mediated by Podocyte TRPC6$303,427
R01 · FY2013 · DK · contact PI
Enzymatic Regulation of the Podocyte$221,468
R01 · FY2013 · DK · contact PI
Glomerular Disease Mechanisms mediated by Podocyte TRPC6$243,612
R01 · FY2012 · DK · contact PI
Enzymatic Regulation of the Podocyte$229,500
R01 · FY2012 · DK · contact PI
Glomerular Disease Mechanisms mediated by Podocyte TRPC6$72,276
R01 · FY2012 · DK · contact PI
Glomerular Disease Mechanisms mediated by Podocyte TRPC6$319,582
R01 · FY2011 · DK · contact PI
Glomerular Disease Mechanisms mediated by Podocyte TRPC6$388,876
R01 · FY2010 · DK · contact PI
Proteolytic Regulation of Podocyte Function by Cathepsin L$265,931
R01 · FY2010 · DK · contact PI
Proteolytic Regulation of Podocyte Function by Cathepsin L$247,224
R01 · FY2009 · DK · contact PI
Proteolytic Regulation of Podocyte Function by Cathepsin L$100,000
R01 · FY2009 · DK · contact PI
Proteolytic Regulation of Podocyte Function by Cathepsin L$152,080
R01 · FY2008 · DK · contact PI
Proteolytic Regulation of Podocyte Function by Cathepsin L$148,780
R01 · FY2008 · DK · contact PI
Proteolytic Regulation of Podocyte Function by Cathepsin L$307,000
R01 · FY2007 · DK · contact PI
Proteolytic Regulation of Podocyte Function by Cathepsin L.$316,168
R01 · FY2006 · DK · contact PI